Results 201 to 210 of about 52,371 (280)

HIV and Antiretroviral Therapy Influence Tumor Microenvironment Architecture, Subclonal Evolution, and Immune Evasion Strategies in Diffuse Large B-cell Lymphoma. [PDF]

Cancer Res Commun
Coelho J, Roush SM, Beck S, Wielgus A, Xu AM, Chirwa A, Mponda M, Kasonkanji E, Mulenga M, Tomoka T, Gopal S, Merchant A, Painschab MS, Fedoriw Y.   +13 more
europepmc   +1 more source

Integrative analysis of m6A-related genetic variants and single-cell RNA sequencing identifies HLA-DQA1/HLA-DQB1-associated immune signatures in CAR-T-treated diffuse large B-cell lymphoma. [PDF]

Transl Oncol
Jian JM, Yuan CL, Hao HY.
europepmc   +1 more source

Circulating Tumor DNA and Immune Response Markers for Improved Treatment Outcome Prediction in Diffuse Large B-Cell Lymphoma: A Scoping Review. [PDF]

Hematol Oncol
McMahon A, Ryan EJ, Dillon S, Clifford R.   +3 more
europepmc   +1 more source

Chemotherapy-Free Polatuzumab Vedotin and Rituximab (Pola-R) for Frail, Older Patients with Relapsed DLBCL: A Case for Geriatric Assessment and Shared Decision-Making. [PDF]

Reports (MDPI)
Horaguchi R, Kikuchi S, Ono K, Minemura T, Sato T.   +4 more
europepmc   +1 more source

Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry study. [PDF]

BMC Cancer
von Kroge S, Steinhaus NJ, Bokemeyer C, Tetzlaff F, Walk H, Kusche H, LYSED study group, Peters F.   +7 more
europepmc   +1 more source

Primary Diffuse Large B-cell Lymphoma of the Urinary Bladder: A Case Report and Narrative Review of Treatment Modalities and Clinical Outcomes. [PDF]

Cureus
Abdullah RM, Raybon KB, Stisser B, Wenzinger CJ.   +3 more
europepmc   +1 more source